Skip to main content

ResearchDx, CompanDx Form Partnership Aimed at Companion Dx Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ResearchDx today announced a partnership with CompanDx that it said will result in "a full capability to discover and deliver novel molecular diagnostic tests."

The collaboration draws on ResearchDx's ability to design, produce, and validate tests, and CompanDx's Distiller platform to deliver small composite biomarker signatures from complex data of high dimensionality. As a result, clients will be able to initiate the parallel development of companion diagnostics from the earliest stages of drug development, ResearchDx said.

Financial and other terms of the deal were not disclosed.

Based in Irvine, Calif., ResearchDx is a contract diagnostics organization for the biopharmaceutical and diagnostic industries.

CompanDx is a molecular diagnostics firm based in Nottingham, UK. Earlier this year it and Clinical Reference Laboratory announced a collaboration to develop biomarker panels and companion diagnostics.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.